Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) belong to an important therapeutic class for treatment of type 2 diabetes. Six GLP-1 RAs, each utilizing a unique drug delivery strategy, are now approved by the Food and Drug Administration (FDA) and additional, novel GLP-1 RAs are still under development, making for a crowded marketplace and fierce competition among the manufacturers of these products. As rapid elimination is a major challenge for clinical application of GLP-1 RAs, various half-life extension strategies have been successfully employed including sequential modification, attachment of fatty-acid to peptide, fusion with human serum albumin, fusion with the fragment crystallizable (Fc) region of a monoclonal antibody, sustained drug delivery systems, and PEGylation. In this review, we discuss the scientific rationale of the various half-life extension strategies used for GLP-1 RA development. By analyzing and comparing different approved GLP-1 RAs and those in development, we focus on assessing how half-life extending strategies impact the pharmacokinetics, pharmacodynamics, safety, patient usability and ultimately, the commercial success of GLP-1 RA products. We also anticipate future GLP-1 RA development tre...Continue Reading
Citations
Apr 9, 2019·Expert Opinion on Emerging Drugs·Eun Ji ParkDong Hee Na
Jan 5, 2020·The AAPS Journal·Wenzhan YangManuel Sanchez-Felix
Aug 12, 2019·Gut·Yining XuAna Beloqui
Apr 30, 2020·Journal of Nanobiotechnology·Xiaoyan BaoPing Yao
Mar 17, 2020·Diabetes, Obesity & Metabolism·Kun-Ho YoonChristopher H Sorli
Jul 4, 2020·Expert Opinion on Drug Delivery·Shuying WangW John Kao
Jul 20, 2019·Diabetes Care·Julio RosenstockKun-Ho Yoon
Jan 4, 2020·The AAPS Journal·Chester E MarkwalterRobert K Prud'homme
Nov 22, 2019·Scientific Reports·Yazhou LiNigel H Greig
Jun 24, 2020·Cardiovascular Diabetology·Osamah M AlfayezMajed S Al Yami
Dec 16, 2018·Journal of Controlled Release : Official Journal of the Controlled Release Society·Camilla Kaas FrichAlexander N Zelikin
Oct 31, 2020·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Tinghui LiSteven P Schwendeman
Jan 13, 2021·ACS Chemical Neuroscience·Muhammad ImranShupeng Li
Jan 24, 2021·Advanced Drug Delivery Reviews·Renjie LiuGregory A Hudalla
Jan 9, 2021·Journal of Controlled Release : Official Journal of the Controlled Release Society·Yanan WangZhiyu He
Jan 9, 2021·Signal Transduction and Targeted Therapy·Dehua YangMing-Wei Wang
Jul 4, 2020·Journal of Controlled Release : Official Journal of the Controlled Release Society·Seung Ho LeeYoung Bin Choy
Apr 13, 2021·Bioconjugate Chemistry·Seyed Ebrahim AlaviPeter M Moyle
May 15, 2021·Advanced Materials·Yongsheng GaoSamir Mitragotri
May 21, 2021·International Journal of Pharmaceutics·Sonja KinnaMark E Welland
May 9, 2021·Journal of Biochemistry·Nobuko KuroishiKazuo Kitamura
Jun 27, 2021·BMJ Open Diabetes Research & Care·Marcus HompeschLinda Morrow
Jul 24, 2021·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Kristina S BoyeLouis S Matza
Jul 28, 2021·Advanced Drug Delivery Reviews·Virender KumarRam I Mahato
Apr 17, 2019·Molecular Pharmaceutics·Jameson R BotheSandhya Kashi
Nov 20, 2020·ACS Nano·Chester E MarkwalterPablo G Debenedetti
Aug 29, 2021·Pharmaceutics·Alexander BenetAnna Schwendeman